{"transactions":[{"id":749763,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":41382,"kind":"person","name":"KANTOFF AARON","position":1,"cik":"0001862734","reported_name":"KANTOFF AARON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-04T20:10:12.000Z","date":"2026-06-02","kind":"grant","planned":false,"acquired":true,"shares":20100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests 100% on the first anniversary of the date of grant, subject to the director's continued service on such vesting date."}],"balance_after":20100,"derivative":{"exercise_price":13.96,"expiration_date":"2036-06-02","underlying":"Common Stock","underlying_shares":20100},"source":{"system":"sec-edgar","filing":"0001862734-26-000004","document":"form4-06042026_040605.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1862734/000186273426000004/form4-06042026_040605.xml","form_type":"4"}},{"id":824230,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":41382,"kind":"person","name":"KANTOFF AARON","position":1,"cik":"0001862734","reported_name":"KANTOFF AARON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-03-31T20:12:48.000Z","date":"2026-03-28","kind":"exercise","planned":false,"acquired":false,"shares":3166,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On August 13, 2024, the Reporting Person was granted 9,500 restricted stock units, vesting 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027, subject to the Reporting Person's continued service on such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On August 13, 2024, the Reporting Person was granted 9,500 restricted stock units, vesting 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":3167,"derivative":{"underlying":"Common Stock","underlying_shares":3166},"source":{"system":"sec-edgar","filing":"0001862734-26-000002","document":"form4-03312026_080342.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1862734/000186273426000002/form4-03312026_080342.xml","form_type":"4"}},{"id":824229,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":41382,"kind":"person","name":"KANTOFF AARON","position":1,"cik":"0001862734","reported_name":"KANTOFF AARON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-31T20:12:48.000Z","date":"2026-03-28","kind":"exercise","planned":false,"acquired":true,"shares":3166,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":6333,"source":{"system":"sec-edgar","filing":"0001862734-26-000002","document":"form4-03312026_080342.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1862734/000186273426000002/form4-03312026_080342.xml","form_type":"4"}},{"id":1012643,"issuer":{"id":15643,"kind":"organization","name":"Tourmaline Bio, Inc.","symbol":"TRML"},"owners":[{"id":41382,"kind":"person","name":"KANTOFF AARON","position":1,"cik":"0001862734","reported_name":"KANTOFF AARON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-10-28T22:30:17.000Z","date":"2025-10-28","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":16800,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of September 8, 2025, by and among Issuer, Novartis AG, a company limited by shares (Aktiengesellschaft) incorporated under the laws of Switzerland (\"Parent\"), and Torino Merger Sub Inc., a Delaware corporation and indirect wholly owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, on October 28, 2025, Merger Sub completed a cash tender offer to acquire all of the shares of common stock of the Issuer, par value $0.0001 (the \"Shares\"), issued and outstanding immediately prior to the effective time of the merger (the \"Effective Time\"), in exchange for $48.00 in cash per Share, subject to any applicable withholding of taxes (the \"Merger Consideration\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes."}],"balance_after":0,"derivative":{"exercise_price":18.73,"underlying":"Common Stock","underlying_shares":16800},"source":{"system":"sec-edgar","filing":"0001862734-25-000006","document":"form4-10282025_061013.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1862734/000186273425000006/form4-10282025_061013.xml","form_type":"4"}},{"id":1012642,"issuer":{"id":15643,"kind":"organization","name":"Tourmaline Bio, Inc.","symbol":"TRML"},"owners":[{"id":41382,"kind":"person","name":"KANTOFF AARON","position":1,"cik":"0001862734","reported_name":"KANTOFF AARON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-10-28T22:30:17.000Z","date":"2025-10-28","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of September 8, 2025, by and among Issuer, Novartis AG, a company limited by shares (Aktiengesellschaft) incorporated under the laws of Switzerland (\"Parent\"), and Torino Merger Sub Inc., a Delaware corporation and indirect wholly owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, on October 28, 2025, Merger Sub completed a cash tender offer to acquire all of the shares of common stock of the Issuer, par value $0.0001 (the \"Shares\"), issued and outstanding immediately prior to the effective time of the merger (the \"Effective Time\"), in exchange for $48.00 in cash per Share, subject to any applicable withholding of taxes (the \"Merger Consideration\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes."}],"balance_after":0,"derivative":{"exercise_price":13.91,"underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001862734-25-000006","document":"form4-10282025_061013.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1862734/000186273425000006/form4-10282025_061013.xml","form_type":"4"}},{"id":1012641,"issuer":{"id":15643,"kind":"organization","name":"Tourmaline Bio, Inc.","symbol":"TRML"},"owners":[{"id":41382,"kind":"person","name":"KANTOFF AARON","position":1,"cik":"0001862734","reported_name":"KANTOFF AARON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-10-28T22:30:17.000Z","date":"2025-10-28","kind":"other","planned":false,"acquired":false,"shares":88281,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of September 8, 2025, by and among Issuer, Novartis AG, a company limited by shares (Aktiengesellschaft) incorporated under the laws of Switzerland (\"Parent\"), and Torino Merger Sub Inc., a Delaware corporation and indirect wholly owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, on October 28, 2025, Merger Sub completed a cash tender offer to acquire all of the shares of common stock of the Issuer, par value $0.0001 (the \"Shares\"), issued and outstanding immediately prior to the effective time of the merger (the \"Effective Time\"), in exchange for $48.00 in cash per Share, subject to any applicable withholding of taxes (the \"Merger Consideration\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, each Share was tendered in exchange for $48.00 in cash per Share."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001862734-25-000006","document":"form4-10282025_061013.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1862734/000186273425000006/form4-10282025_061013.xml","form_type":"4"}},{"id":1013875,"issuer":{"id":15643,"kind":"organization","name":"Tourmaline Bio, Inc.","symbol":"TRML"},"owners":[{"id":41382,"kind":"person","name":"KANTOFF AARON","position":1,"cik":"0001862734","reported_name":"KANTOFF AARON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-10-24T22:10:19.000Z","date":"2025-10-24","kind":"gift","planned":false,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares donated to a donor-advised fund, which will use the gifted shares for charitable purposes."}],"balance_after":88281,"source":{"system":"sec-edgar","filing":"0001862734-25-000004","document":"form4-10242025_101016.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1862734/000186273425000004/form4-10242025_101016.xml","form_type":"4"}},{"id":1044903,"issuer":{"id":15643,"kind":"organization","name":"Tourmaline Bio, Inc.","symbol":"TRML"},"owners":[{"id":41382,"kind":"person","name":"KANTOFF AARON","position":1,"cik":"0001862734","reported_name":"KANTOFF AARON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-09T22:00:06.000Z","date":"2025-09-05","kind":"exercise","planned":false,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option are fully vested and immediately exercisable."}],"balance_after":0,"derivative":{"exercise_price":9.46,"expiration_date":"2033-10-22","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001415889-25-023997","document":"form4-09092025_060901.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1862734/000141588925023997/form4-09092025_060901.xml","form_type":"4"}},{"id":1044902,"issuer":{"id":15643,"kind":"organization","name":"Tourmaline Bio, Inc.","symbol":"TRML"},"owners":[{"id":41382,"kind":"person","name":"KANTOFF AARON","position":1,"cik":"0001862734","reported_name":"KANTOFF AARON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-09T22:00:06.000Z","date":"2025-09-05","kind":"exercise","planned":false,"acquired":false,"shares":37890,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option are fully vested and immediately exercisable."}],"balance_after":0,"derivative":{"exercise_price":0.13,"expiration_date":"2033-02-02","underlying":"Common Stock","underlying_shares":37890},"source":{"system":"sec-edgar","filing":"0001415889-25-023997","document":"form4-09092025_060901.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1862734/000141588925023997/form4-09092025_060901.xml","form_type":"4"}},{"id":1044901,"issuer":{"id":15643,"kind":"organization","name":"Tourmaline Bio, Inc.","symbol":"TRML"},"owners":[{"id":41382,"kind":"person","name":"KANTOFF AARON","position":1,"cik":"0001862734","reported_name":"KANTOFF AARON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-09T22:00:06.000Z","date":"2025-09-05","kind":"exercise","planned":false,"acquired":true,"shares":10000,"price":9.46,"value":94600.0,"ownership":{"direct":true},"balance_after":93281,"source":{"system":"sec-edgar","filing":"0001415889-25-023997","document":"form4-09092025_060901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1862734/000141588925023997/form4-09092025_060901.xml","form_type":"4"}},{"id":1044900,"issuer":{"id":15643,"kind":"organization","name":"Tourmaline Bio, Inc.","symbol":"TRML"},"owners":[{"id":41382,"kind":"person","name":"KANTOFF AARON","position":1,"cik":"0001862734","reported_name":"KANTOFF AARON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-09T22:00:06.000Z","date":"2025-09-05","kind":"exercise","planned":false,"acquired":true,"shares":37890,"price":0.13,"value":4925.7,"ownership":{"direct":true},"balance_after":83281,"source":{"system":"sec-edgar","filing":"0001415889-25-023997","document":"form4-09092025_060901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1862734/000141588925023997/form4-09092025_060901.xml","form_type":"4"}},{"id":1106463,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":41382,"kind":"person","name":"KANTOFF AARON","position":1,"cik":"0001862734","reported_name":"KANTOFF AARON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-18T20:25:59.000Z","date":"2025-06-17","kind":"grant","planned":false,"acquired":true,"shares":20100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests 100% on the first anniversary of the date of grant, subject to the Eligible Director's continued service on such vesting date."}],"balance_after":20100,"derivative":{"exercise_price":4.47,"expiration_date":"2035-06-17","underlying":"Common Stock","underlying_shares":20100},"source":{"system":"sec-edgar","filing":"0001578563-25-000321","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1862734/000157856325000321/primary_doc.xml","form_type":"4"}},{"id":1119903,"issuer":{"id":15643,"kind":"organization","name":"Tourmaline Bio, Inc.","symbol":"TRML"},"owners":[{"id":41382,"kind":"person","name":"KANTOFF AARON","position":1,"cik":"0001862734","reported_name":"KANTOFF AARON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-06T20:41:14.000Z","date":"2025-06-04","kind":"grant","planned":false,"acquired":true,"shares":16800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option vest on the earlier of the anniversary of the Transaction Date or the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":16800,"derivative":{"exercise_price":18.73,"expiration_date":"2035-06-04","underlying":"Common Stock","underlying_shares":16800},"source":{"system":"sec-edgar","filing":"0001827506-25-000084","document":"wk-form4_1749242441.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1862734/000182750625000084/wk-form4_1749242441.xml","form_type":"4"}},{"id":1186590,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":41382,"kind":"person","name":"KANTOFF AARON","position":1,"cik":"0001862734","reported_name":"KANTOFF AARON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-04-01T20:37:21.000Z","date":"2025-03-28","kind":"exercise","planned":false,"acquired":false,"shares":3167,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On August 13, 2024, the Reporting Person was granted 9,500 restricted stock units, vesting 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027, subject to the Reporting Person's continued service on such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On August 13, 2024, the Reporting Person was granted 9,500 restricted stock units, vesting 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":6333,"derivative":{"underlying":"Common Stock","underlying_shares":3167},"source":{"system":"sec-edgar","filing":"0001578563-25-000201","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1862734/000157856325000201/primary_doc.xml","form_type":"4"}},{"id":1186589,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":41382,"kind":"person","name":"KANTOFF AARON","position":1,"cik":"0001862734","reported_name":"KANTOFF AARON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-04-01T20:37:21.000Z","date":"2025-03-28","kind":"exercise","planned":false,"acquired":true,"shares":3167,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":3167,"source":{"system":"sec-edgar","filing":"0001578563-25-000201","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1862734/000157856325000201/primary_doc.xml","form_type":"4"}},{"id":1433868,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":41382,"kind":"person","name":"KANTOFF AARON","position":1,"cik":"0001862734","reported_name":"KANTOFF AARON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2024-08-14T20:36:23.000Z","date":"2024-08-13","kind":"grant","planned":false,"acquired":true,"shares":9500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of common stock upon the vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vest 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027, subject to the Reporting Person's continued service on such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vest 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":9500,"derivative":{"underlying":"Common Stock","underlying_shares":9500},"source":{"system":"sec-edgar","filing":"0001578563-24-000367","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1862734/000157856324000367/primary_doc.xml","form_type":"4"}},{"id":1433867,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":41382,"kind":"person","name":"KANTOFF AARON","position":1,"cik":"0001862734","reported_name":"KANTOFF AARON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-14T20:36:23.000Z","date":"2024-08-13","kind":"grant","planned":false,"acquired":true,"shares":24600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":24600,"derivative":{"exercise_price":9.88,"expiration_date":"2034-08-13","underlying":"Common Stock","underlying_shares":24600},"source":{"system":"sec-edgar","filing":"0001578563-24-000367","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1862734/000157856324000367/primary_doc.xml","form_type":"4"}},{"id":1487104,"issuer":{"id":15643,"kind":"organization","name":"Tourmaline Bio, Inc.","symbol":"TRML"},"owners":[{"id":41382,"kind":"person","name":"KANTOFF AARON","position":1,"cik":"0001862734","reported_name":"KANTOFF AARON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-07T20:02:56.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option vest on the earlier of the anniversary of the Transaction Date or the date of the Issuer's 2025 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":10000,"derivative":{"exercise_price":13.91,"expiration_date":"2034-06-04","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001827506-24-000054","document":"wk-form4_1717790566.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1862734/000182750624000054/wk-form4_1717790566.xml","form_type":"4"}},{"id":1754785,"issuer":{"id":15643,"kind":"organization","name":"Tourmaline Bio, Inc.","symbol":"TRML"},"owners":[{"id":41382,"kind":"person","name":"KANTOFF AARON","position":1,"cik":"0001862734","reported_name":"KANTOFF AARON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-10-26T21:00:17.000Z","date":"2023-10-24","kind":"purchase","planned":false,"acquired":true,"shares":7500,"price":11.86,"value":88950.0,"ownership":{"direct":true},"balance_after":45391,"source":{"system":"sec-edgar","filing":"0001209191-23-053674","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1862734/000120919123053674/doc4.xml","form_type":"4"}},{"id":1756277,"issuer":{"id":15643,"kind":"organization","name":"Tourmaline Bio, Inc.","symbol":"TRML"},"owners":[{"id":41382,"kind":"person","name":"KANTOFF AARON","position":1,"cik":"0001862734","reported_name":"KANTOFF AARON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-10-24T00:24:07.000Z","date":"2023-10-23","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"100% of the shares subject to the option vest on the earlier of October 23, 2024 or the date of the Issuer's 2024 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":10000,"derivative":{"exercise_price":9.46,"expiration_date":"2033-10-22","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-23-053397","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1862734/000120919123053397/doc4.xml","form_type":"4"}},{"id":1756276,"issuer":{"id":15643,"kind":"organization","name":"Tourmaline Bio, Inc.","symbol":"TRML"},"owners":[{"id":41382,"kind":"person","name":"KANTOFF AARON","position":1,"cik":"0001862734","reported_name":"KANTOFF AARON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-10-24T00:24:07.000Z","date":"2023-10-19","kind":"grant","planned":false,"acquired":true,"shares":37890,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Upon the closing of the Merger, each outstanding option to purchase shares of Tourmaline common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, on the same terms and conditions as were applicable to such Tourmaline stock option prior to the Merger, as adjusted for the exchange ratio and the reverse stock split."},{"field":"shares","element":"transactionShares","label":"F3","text":"Upon the closing of the Merger, each outstanding option to purchase shares of Tourmaline common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, on the same terms and conditions as were applicable to such Tourmaline stock option prior to the Merger, as adjusted for the exchange ratio and the reverse stock split."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Upon the closing of the Merger, each outstanding option to purchase shares of Tourmaline common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, on the same terms and conditions as were applicable to such Tourmaline stock option prior to the Merger, as adjusted for the exchange ratio and the reverse stock split."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Received in exchange for a stock option to acquire 475,000 shares of Tourmaline common stock pursuant to the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to the option vest as to 1/3 of the shares on May 6, 2023 with the remainder vesting in the following 24 equal monthly installments, subject to the Reporting Person's continued service on each such vesting date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"Upon the closing of the Merger, each outstanding option to purchase shares of Tourmaline common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, on the same terms and conditions as were applicable to such Tourmaline stock option prior to the Merger, as adjusted for the exchange ratio and the reverse stock split."}],"balance_after":37890,"derivative":{"exercise_price":0.13,"expiration_date":"2033-02-02","underlying":"Common Stock","underlying_shares":37890},"source":{"system":"sec-edgar","filing":"0001209191-23-053397","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1862734/000120919123053397/doc4.xml","form_type":"4"}},{"id":1756275,"issuer":{"id":15643,"kind":"organization","name":"Tourmaline Bio, Inc.","symbol":"TRML"},"owners":[{"id":41382,"kind":"person","name":"KANTOFF AARON","position":1,"cik":"0001862734","reported_name":"KANTOFF AARON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-10-24T00:24:07.000Z","date":"2023-10-19","kind":"grant","planned":false,"acquired":true,"shares":37891,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"2,015 of these shares are subject to a repurchase option in favor of the Issuer in the event that the Reporting Person's continuous service is terminated. Such repurchase option shall lapse in equal monthly installments until such shares are fully vested on June 1, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Received in exchange for 475,000 shares of common stock of Tourmaline Bio, Inc. (\"Tourmaline\") pursuant to an Agreement and Plan of Merger dated as of June 22, 2023 (the \"Merger Agreement\") by and among Tourmaline, the Issuer and Terrain Merger Sub, Inc., a wholly owned subsidiary of the Issuer (\"Merger Sub\"). Under the terms of the Merger Agreement, on October 19, 2023, Merger Sub merged with and into Tourmaline (the \"Merger\"), with Tourmaline surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, each share of Tourmaline common stock was converted into the right to receive 0.07977 of a share of the Issuer's common stock, after giving effect to a reverse stock split of the Issuer's common stock of 10-for-1. Subsequent to the Merger, the name of the Issuer was changed from Talaris Therapeutics, Inc. to Tourmaline Bio, Inc."}],"balance_after":37891,"source":{"system":"sec-edgar","filing":"0001209191-23-053397","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1862734/000120919123053397/doc4.xml","form_type":"4"}},{"id":2505106,"issuer":{"id":35581,"kind":"organization","name":"Centessa Pharmaceuticals plc","symbol":"CNTA"},"owners":[{"id":41382,"kind":"person","name":"KANTOFF AARON","position":1,"cik":"0001862734","reported_name":"KANTOFF AARON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2021-11-19T01:30:09.000Z","date":"2021-11-18","kind":"purchase","acquired":true,"shares":10000,"price":11.985,"value":119850.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":60000,"source":{"system":"sec-edgar","filing":"0000899243-21-045321","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1862734/000089924321045321/doc4.xml","form_type":"4"}}]}